Summary by Futu AI
Andrew Shutterly, Acting Chief Financial Officer of Altimmune, Inc., completed a purchase of 1,259 shares of common stock on July 31, 2024. The transaction was carried out at a price of $5.41 per share, resulting in a total investment of approximately $6,811.99. Following this acquisition, Shutterly's direct holdings in the company increased to 11,372 shares of common stock. The transaction reflects a direct ownership interest and is reported as a grant, award, or other acquisition in line with the transaction code 'A'.